The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
Open accessAbstract
Gain of chromosome 1q (+1q) is commonly identified in multiple myeloma and has been associated with inferior outcomes. However, the prognostic implication of +1q has not been evaluated in the setting of standard triplet regimens. We retrospectively analyzed 201 consecutive patients with newly diagnosed myeloma who received induction with lenalidomide, bortezomib, and dexamethasone (RVD) and were tested for +1q at diagnosis by fluorescent in-situ hybridization. Patients with +1q (n = 94), compared to those without +1q (n = 107), had shorter median progression-free survival (PFS) (41.9 months vs 65.1 months, p = 0.002, HR = 1.90) and overall survival (median not reached (NR) for either arm, p = 0.003, HR 2.69). In subgroup analyses, patients with co-occurring +1q and t(4;14), t(14;16) or del(17p) or with 4 or more copies of 1q had significantly worse PFS (25.1 months and 34.6 months, p < 0.001 and p = 0.0063, respectively), whereas patients with three copies and no other high-risk cytogenetic abnormalities had no significant difference in PFS. These data suggest that when treated with RVD induction, patients with +1q should be considered at very high risk for early progression in multiple myeloma when ≥4 copies are detected or in the context of other high-risk cytogenetic abnormalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210
Self-citationLenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908
Cited by
Diagnosis and Management of Multiple Myeloma: A Review
Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L. A., Tuazon, S., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,029
D'Agostino, M., Cairns, D. A., Lahuerta, J. J., Wester, R., Bertsch, U., Waage, A., Zamagni, E., Mateos, M.-V., Dall'Olio, D., van de Donk, N. W. C. J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02614 · Cited by 429
Maclachlan, K. H., Rustad, E. H., Derkach, A., Zheng-Lin, B., Yellapantula, V., Diamond, B., Hultcrantz, M., Ziccheddu, B., Boyle, E. M., Blaney, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25469-8 · Cited by 49
Temporal genomic dynamics shape clinical trajectory in multiple myeloma
Maura, F., Kaddoura, M., Poos, A. M., Baughn, L. B., Ziccheddu, B., Bärtsch, M.-A., Cirrincione, A., Maclachlan, K., Chojnacka, M., Diamond, B., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02292-1 · Cited by 14
Ang, D. A., Carter, J.-M., Deka, K., Tan, J. H. L., Zhou, J., Chen, Q., Chng, W. J., Harmston, N., & Li, Y. (2024) · Nature Communications · doi:10.1038/s41467-024-46728-4 · Cited by 13
“1q gain in particular has been shown to be associated with worse prognosis in newly diagnosed and relapsed MM patients 43 – 46 .”
Metadata
- Authors
- Schmidt, T. M., Barwick, B. G., Joseph, N., Heffner, L. T., Hofmeister, C. C., Bernal, L., Dhodapkar, M. V., Gupta, V. A., Jaye, D. L., Wu, J., Goyal, S., Chen, Z., Boise, L. H., Lonial, S., Nooka, A. K., & Kaufman, J. L.
- Venue
- Blood Cancer Journal
- Published
- 2019-11-25
- Volume
- 9
- Issue
- 12
- Pages
- 94-94
- ISSN
- 2044-5385 (ISSN-L)
- OpenAlex
- W2990865799
- Cited by
- 162
- References
- 3
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. https://app.cochat.ai/papers/10.1038/s41408-019-0254-0
- The paper
- Schmidt, T. M., Barwick, B. G., Joseph, N., Heffner, L. T., Hofmeister, C. C., Bernal, L., Dhodapkar, M. V., Gupta, V. A., Jaye, D. L., Wu, J., Goyal, S., Chen, Z., Boise, L. H., Lonial, S., Nooka, A. K., & Kaufman, J. L. (2019). Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer Journal. https://doi.org/10.1038/s41408-019-0254-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.